SECsense Logo

Aptose Biosciences Inc. 8-K Filing: Key Updates on January 9, 2025

$APTO
Form 8-K
Filed on: 2025-01-10
Source
Aptose Biosciences Inc. 8-K Filing: Key Updates on January 9, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Filing Type: The document is an 8-K filing, which is typically used to report major events that shareholders should know about.
  2. Company Information:
  • Name: Aptose Biosciences Inc.
  • CIK: 0000882361
  • Address: 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, ON M5K 1E6
  • Phone: 310-849-8060
  • Ticker Symbol: APTO
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: January 9, 2025
  • End Date: January 9, 2025
  1. Units of Measurement:
  • Financial metrics are reported in U.S. Dollars (USD).
  • Shares are also referenced, indicating potential share-related disclosures.
  1. Identification Numbers:
  • Central Index Key (CIK): 0000882361
  • IRS Employer Identification Number (EIN): 98-1136802
  • Securities and Exchange Commission (SEC) File Number: 001-32001
  1. Share Information:
  • Type of Shares: Common Shares, no par value.

Insights:

  • The 8-K filing indicates that significant corporate information or events occurred on January 9, 2025, which may impact stakeholders.
  • The context of shares suggests that the filing may relate to stock issuance, stock buybacks, or other corporate actions affecting share capital.
  • The company is listed on NASDAQ, indicating a necessity for compliance with SEC regulations for public companies.

This information is critical for investors and analysts monitoring Aptose Biosciences Inc., as it highlights a specific reporting event that could influence the company's market performance or operational strategy.